Antibody Category
Suppliers
Applications
Antibody Types
Host Species
Species Reactivity
  • Category A

    • Original source/host: Naïve (human-derived B cell) or synthetic, natural or consensus framework (any species, published framework sequences) antibody or mimetic
    • Discovery method: Non-immunisation based in vitro display selection of antibody or mimetic
    • Production: Recombinant expression with no use of animal-derived biomaterials in production or final formulation
    Search
  • Category B

    • Original source/host: Animal (historic hybridoma) OR naïve, non-immunised animal B cell-derived in vitro antibody display library
    • Discovery method: immunisation pre-2020 OR in vitro display selection of antibodies
    • Production: Recombinant expression with no use of animal-derived biomaterials in production or final formulation
    • Recombinantly reformatted hybridomas are included as they align with the May 2020 EURL ECVAM recommendation, which permits continued use of existing, sequenced, and well-characterised hybridomas to produce recombinant monoclonal antibodies in vitro, as animals are no longer directly involved
    • Naïve, non-immunised animal B cell-derived in vitro antibody display libraries align with the May 2020 EURL ECVAM recommendation to no longer authorise the development and production of antibodies through animal immunisation
    Search
  • Category C

    • Original source/host: Naïve (human-derived B cell) or synthetic, natural or consensus framework (any species, published framework sequences) antibody or mimetic
    • Discovery method: Non-immunisation based in vitro display selection of antibody or mimetic
    • Production: Recombinant expression ; animal-derived biomaterials used in production or final formulation
    Search
  • Category D

    • Original source/host: Animal OR naïve, non-immunised animal B cell-derived in vitro antibody display library
    • Discovery method: immunisation pre-2020 OR in vitro display selection of antibodies
    • Production: Recombinant expression ; animal-derived biomaterials used in production or final formulation
    Search
  • Category E

    • Original source/host: Animal
    • Discovery method: immunisation-based selection post 2020
    • Production: Recombinant expression with no use of animal-derived biomaterials in production or final formulation
    Search
  • Category F

    • Original source/host: Animal
    • Discovery method: immunisation-based selection post 2020
    • Production: Recombinant expression with animal-derived biomaterials used in production or final formulation
    Search
  • Category G

    • Original source/host: Unknown
    • Discovery method: Unknown
    • Production: Recombinant expression with no use of animal-derived biomaterials in production or final formulation
    Search

Anti-Human 4-1BB Ligand/TNFSF9 Reference Antibody (EU101, RUO)


View Antibody details

Anti-Human 4-1BB Ligand/TNFSF9 Reference Antibody (Evunzekibart, RUO)


View Antibody details

Anti-Human 4-1BB Ligand/TNFSF9 Reference Antibody (Exlinkibart, RUO)


View Antibody details

Anti-Human 4-1BB Ligand/TNFSF9 Reference Antibody (HOT-1030, RUO)


View Antibody details

Anti-Human 4-1BB Ligand/TNFSF9 Reference Antibody (LVGN6051, RUO)


View Antibody details

Anti-Human 4-1BB Ligand/TNFSF9 Reference Antibody (Urelumab, RUO)


View Antibody details

Anti-Human 4-1BB Ligand/TNFSF9 Reference Antibody (Utomilumab, RUO)


View Antibody details

Anti-Human 4-1BB Ligand/TNFSF9 Reference Antibody (YH-004, RUO)


View Antibody details

Anti-Human 4-1BB Ligand/TNFSF9&CD19 Reference Antibody (Ensomafusp Alfa, RUO)


View Antibody details

Anti-Human 4-1BB/TNFRSF9/CD137 & CD3 epsilon & DLL3 Reference Antibody (Clesitamig, RUO)


View Antibody details